MXPA03010195A - Derivados de ciclohexan-1,4-diamina sustituidos con actividad antiarreica y analgesica periferica. - Google Patents

Derivados de ciclohexan-1,4-diamina sustituidos con actividad antiarreica y analgesica periferica.

Info

Publication number
MXPA03010195A
MXPA03010195A MXPA03010195A MXPA03010195A MXPA03010195A MX PA03010195 A MXPA03010195 A MX PA03010195A MX PA03010195 A MXPA03010195 A MX PA03010195A MX PA03010195 A MXPA03010195 A MX PA03010195A MX PA03010195 A MXPA03010195 A MX PA03010195A
Authority
MX
Mexico
Prior art keywords
constipating
diamine derivatives
analgesic properties
pains
peripheral analgesic
Prior art date
Application number
MXPA03010195A
Other languages
English (en)
Inventor
Elmar Josef Friderichs
Original Assignee
Gr Nenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gr Nenthal Gmbh filed Critical Gr Nenthal Gmbh
Publication of MXPA03010195A publication Critical patent/MXPA03010195A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/36—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invencion se refiere al uso de derivados de 1,4-diamina sustituidos para la preparacion de medicamentos para el tratamiento de diarrea o "enfermedades de irritacion intestinal" o para el uso como agentes de inmunoterapia o como analgesico periferico, particularmente para el tratamiento de dolor de quemaduras, dolores perifericos quirurgicos, inflamaciones de tejido blando o enfermedades inflamatorias de las articulaciones, particularmente reumatismo.
MXPA03010195A 2001-05-09 2002-05-09 Derivados de ciclohexan-1,4-diamina sustituidos con actividad antiarreica y analgesica periferica. MXPA03010195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10123163A DE10123163A1 (de) 2001-05-09 2001-05-09 Substituierte Cyclohexan-1,4-diaminderivate
PCT/EP2002/005122 WO2002089783A1 (de) 2001-05-09 2002-05-09 Substituierte cyclohexan-1,4-diaminderivate mit antidiarrhoeischer und peripher analgetischer wirksamkeit

Publications (1)

Publication Number Publication Date
MXPA03010195A true MXPA03010195A (es) 2004-03-10

Family

ID=7684562

Family Applications (3)

Application Number Title Priority Date Filing Date
MXPA03010134A MXPA03010134A (es) 2001-05-09 2002-05-08 Derivados de ciclohexan-1-4-diamina sustituidos.
MXPA03010201A MXPA03010201A (es) 2001-05-09 2002-05-08 Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
MXPA03010195A MXPA03010195A (es) 2001-05-09 2002-05-09 Derivados de ciclohexan-1,4-diamina sustituidos con actividad antiarreica y analgesica periferica.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MXPA03010134A MXPA03010134A (es) 2001-05-09 2002-05-08 Derivados de ciclohexan-1-4-diamina sustituidos.
MXPA03010201A MXPA03010201A (es) 2001-05-09 2002-05-08 Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.

Country Status (31)

Country Link
US (3) US20040229872A1 (es)
EP (3) EP1385825B1 (es)
JP (3) JP2004528374A (es)
KR (2) KR100895778B1 (es)
CN (2) CN1307158C (es)
AR (1) AR035883A1 (es)
AT (2) ATE370120T1 (es)
AU (3) AU2002341195B2 (es)
BR (2) BR0209579A (es)
CA (3) CA2446461C (es)
CO (2) CO5540300A2 (es)
CY (2) CY1106468T1 (es)
CZ (2) CZ20032995A3 (es)
DE (3) DE10123163A1 (es)
DK (2) DK1392641T3 (es)
EC (2) ECSP034830A (es)
ES (2) ES2291486T3 (es)
HK (2) HK1062911A1 (es)
HU (3) HU228253B1 (es)
IL (4) IL158784A0 (es)
MX (3) MXPA03010134A (es)
NO (2) NO326784B1 (es)
NZ (2) NZ529147A (es)
PE (1) PE20021094A1 (es)
PL (3) PL220595B1 (es)
PT (2) PT1385825E (es)
RU (2) RU2321579C2 (es)
SI (2) SI1385825T1 (es)
SK (2) SK287319B6 (es)
WO (3) WO2002090330A1 (es)
ZA (2) ZA200309521B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252665A1 (de) 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252650A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Cyclohexyl-Harnstoff-Derivate
ATE457299T1 (de) 2002-11-12 2010-02-15 Gruenenthal Gmbh 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
JP4206382B2 (ja) 2002-11-19 2009-01-07 アキリオン ファーマシューティカルズ，インコーポレーテッド 置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004023506A1 (de) * 2004-05-10 2005-12-01 Grünenthal GmbH Kettenverlängerte substituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023508A1 (de) 2004-05-10 2005-12-08 Grünenthal GmbH Säurederivate substituierter Cyclohexyl-1,4-diamine
DE102004023632A1 (de) 2004-05-10 2005-12-08 Grünenthal GmbH Substituierte Cyclohexylcarbonsäure-Derivate
DE102004023501A1 (de) 2004-05-10 2005-12-01 Grünenthal GmbH Oxosubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023507A1 (de) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituierte Cyclohexylessigsäure-Derivate
DE102004023635A1 (de) 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102004023522A1 (de) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituierte Cyclohexyl-1,4-diamin-Derivate
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
DE102005061428A1 (de) * 2005-12-22 2007-08-16 Grünenthal GmbH Substituierte Cyclohexylmethyl-Derivate
DE102006033114A1 (de) 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
DE102006035787A1 (de) 2006-07-28 2008-03-13 Tesa Ag Verfahren zum Stanzen von bei Raumtemperatur nicht tackigen hitzeaktivierbaren Klebmassen
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
EP2166841A4 (en) * 2007-06-15 2014-05-07 Mission Pharma Co METHODS AND COMPOSITIONS FOR INHIBITING DOME FACTOR AND ADENYLYLCYCLASE
US20090215725A1 (en) * 2008-02-26 2009-08-27 Grunenthal Gmbh Substituted 4-aminocyclohexane derivatives
ATE525379T1 (de) 2008-03-27 2011-10-15 Gruenenthal Gmbh Substituierte spirocyclische cyclohexan-derivate
WO2009118163A1 (de) 2008-03-27 2009-10-01 Grünenthal GmbH (hetero-)aryl-cyclohexan-derivate
CA2719739A1 (en) 2008-03-27 2009-10-01 Sven Frormann Hydroxymethylcyclohexylamines
MX2010010339A (es) 2008-03-27 2010-10-07 Gruenenthal Gmbh Ciclohexildiaminas sustituidas.
CA2719735A1 (en) * 2008-03-27 2009-10-01 Gruenenthal Gmbh Substituted 4-aminocyclohexane derivatives
SI2257526T1 (sl) 2008-03-27 2012-01-31 Gruenenthal Chemie Spiro(5.5)undekanski derivati
RS52590B2 (sr) 2008-07-21 2018-05-31 Purdue Pharma Lp Jedinjenja tipa supstituisanog hinoksalina sa premošćenim piperidinom i njihova upotreba
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
MX338041B (es) 2009-09-25 2016-03-30 Oryzon Genomics Sa Inhibidores de demetilasa-1 especificos de lisina y su uso.
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
KR101794020B1 (ko) 2010-04-19 2017-11-06 오리존 지노믹스 에스.에이. 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
LT2598482T (lt) 2010-07-29 2018-07-10 Oryzon Genomics, S.A. Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
EP3495349B1 (en) 2011-10-20 2023-06-28 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU172460B (hu) * 1975-10-03 1978-09-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 5,6-digidro-3h-pirimidin-4-ona
US4065573A (en) * 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US4447454A (en) * 1977-04-01 1984-05-08 The Upjohn Company Analgetic compounds, compositions and process of treatment
US5877277A (en) 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US4906655A (en) 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
FR2687147A1 (fr) 1992-02-11 1993-08-13 Union Pharma Scient Appl Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5620955A (en) 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
EP0761220A1 (en) 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamides as growth hormone secretagogues
JP2001500850A (ja) 1996-08-22 2001-01-23 ワーナー―ランバート・コンパニー 非―ペプチドボンベシン受容体アンタゴニスト
US6423725B1 (en) * 1998-01-19 2002-07-23 Pfizer Inc 4-(2-keto-1-benzimidazolinyl)piperidine compounds as ORL1-receptor agonists
US20020169101A1 (en) 1999-05-10 2002-11-14 Gonzalez Maria Isabel Treatment of sexual dysfunction
GB0006289D0 (en) 2000-03-15 2000-05-03 Smithkline Beecham Plc New use
GB0012240D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
US6991916B2 (en) 2000-07-14 2006-01-31 Pfizer Inc. Compounds for the treatment of sexual dysfunction
NZ525630A (en) * 2000-10-06 2004-10-29 Tanabe Seiyaku Co Nitrogen-containing 5-membered ring compound used as dipeptidylpeptidase IV (DPPIV) inhibitor
US20020055759A1 (en) 2000-11-06 2002-05-09 Shibuya Terry Y. Bioactive surgical suture
US20040039198A1 (en) 2000-11-16 2004-02-26 Bender Paul E. Compounds
JP2004522710A (ja) 2000-11-17 2004-07-29 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 性機能障害の治療
GB2369118A (en) 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
IL155814A0 (en) 2000-11-17 2003-12-23 Warner Lambert Co Treatment of sexual dysfunction using bombesin antagonist
BR0115364A (pt) 2000-11-17 2003-09-23 Warner Lambert Co Tratamento de disfunção sexual
GB2369117A (en) 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
DK1385825T3 (da) 2007-11-05
CA2446461A1 (en) 2002-11-14
AU2002341195B2 (en) 2007-01-04
NO20034930D0 (no) 2003-11-05
PT1385825E (pt) 2007-09-04
NO326784B1 (no) 2009-02-16
SK287319B6 (sk) 2010-07-07
NO20034931L (no) 2004-01-02
PL366631A1 (en) 2005-02-07
HUP0400989A3 (en) 2011-08-29
CZ20032995A3 (cs) 2004-02-18
EP1385825B1 (de) 2007-08-15
IL158784A0 (en) 2004-05-12
DE50210707D1 (de) 2007-09-27
ZA200309521B (en) 2004-09-28
PT1392641E (pt) 2007-05-31
NZ529334A (en) 2004-10-29
SK13782003A3 (sk) 2004-04-06
KR20040002943A (ko) 2004-01-07
HU229288B1 (en) 2013-10-28
HUP0400963A2 (hu) 2004-08-30
BR0209579A (pt) 2004-06-22
ECSP034830A (es) 2004-03-23
PL366662A1 (en) 2005-02-07
US20040229872A1 (en) 2004-11-18
ES2291486T3 (es) 2008-03-01
PL212887B1 (pl) 2012-12-31
JP2005515959A (ja) 2005-06-02
SK286617B6 (sk) 2009-02-05
US20040147741A1 (en) 2004-07-29
EP1385493A1 (de) 2004-02-04
CY1106468T1 (el) 2012-01-25
MXPA03010201A (es) 2006-02-09
IL158782A (en) 2010-04-15
MXPA03010134A (es) 2004-03-10
SI1392641T1 (sl) 2007-10-31
CN1537100A (zh) 2004-10-13
US7276518B2 (en) 2007-10-02
ECSP034831A (es) 2004-03-23
KR20040017214A (ko) 2004-02-26
NO328600B1 (no) 2010-03-29
CA2446461C (en) 2011-04-26
CA2446463C (en) 2010-07-13
PL368851A1 (en) 2005-04-04
RU2287523C2 (ru) 2006-11-20
NO20034930L (no) 2004-01-05
IL158784A (en) 2009-09-01
AU2007202033A1 (en) 2007-05-24
AU2007202033B2 (en) 2010-02-04
WO2002090330A1 (de) 2002-11-14
WO2002089783A1 (de) 2002-11-14
SI1385825T1 (sl) 2008-02-29
CY1108067T1 (el) 2014-02-12
BR0209580A (pt) 2004-06-22
HK1062911A1 (en) 2004-12-03
AR035883A1 (es) 2004-07-21
ZA200309522B (en) 2005-02-23
IL158782A0 (en) 2004-05-12
ATE359260T1 (de) 2007-05-15
HUP0400888A3 (en) 2008-03-28
HU228253B1 (en) 2013-02-28
EP1392641B1 (de) 2007-04-11
CN1533374A (zh) 2004-09-29
EP1392641A1 (de) 2004-03-03
NZ529147A (en) 2006-10-27
RU2003134147A (ru) 2005-05-20
RU2003134145A (ru) 2005-05-20
RU2321579C2 (ru) 2008-04-10
JP2004528374A (ja) 2004-09-16
CA2446735A1 (en) 2002-11-14
EP1385825A1 (de) 2004-02-04
HUP0400989A2 (hu) 2004-08-30
SK13792003A3 (sk) 2004-06-08
DK1392641T3 (da) 2007-07-16
US20040162287A1 (en) 2004-08-19
DE50209929D1 (de) 2007-05-24
WO2002090317A1 (de) 2002-11-14
CO5700725A2 (es) 2006-11-30
JP2004533439A (ja) 2004-11-04
HUP0400888A2 (hu) 2004-07-28
ATE370120T1 (de) 2007-09-15
CO5540300A2 (es) 2005-07-29
CN1307158C (zh) 2007-03-28
ES2284876T3 (es) 2007-11-16
US6998409B2 (en) 2006-02-14
CN1533374B (zh) 2013-08-21
NO20034931D0 (no) 2003-11-05
HK1070049A1 (en) 2005-06-10
PL220595B1 (pl) 2015-11-30
AU2002312883B2 (en) 2007-09-06
CA2446463A1 (en) 2002-11-14
PE20021094A1 (es) 2003-01-25
AU2007202033B8 (en) 2010-03-04
DE10123163A1 (de) 2003-01-16
CZ20033005A3 (en) 2004-03-17
KR100895778B1 (ko) 2009-05-08

Similar Documents

Publication Publication Date Title
MXPA03010195A (es) Derivados de ciclohexan-1,4-diamina sustituidos con actividad antiarreica y analgesica periferica.
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
HK1066482A1 (en) Use os fucans in the treatment of adhesions, arthritis and psoriasis
HK1096392A1 (en) Substituted heterocycles
UA74443C2 (uk) Ліганди 5-нт рецептора та їх використання
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
TW200621765A (en) Substituted phenylaminothiazoles and their use
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
CY1111946T1 (el) To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας
NZ552328A (en) Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
WO2004031105A3 (en) Use of a33 antigens and jam-it
MXPA05009014A (es) Antagonistas del receptor ccr-3.
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
EP1178796A4 (en) AMINOIMIDAZOLE CARBOXAMIDE SALTS USEFUL IN THE PREVENTION AND TREATMENT OF LIVER DISEASE
DK1242410T3 (da) Nye forbindelser
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
AU2002357644A1 (en) Therapeutic agents and corresponding treatments
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
CY1106409T1 (el) Παραγωγα κινολινης
HK1087328A1 (en) Therapeutic composition for autoimmune conditions